Drugs Containing Excipient (Inactive Ingredient) WATER

« Back to Dashboard

Branded drugs containing WATER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	WATER	2028-12-19
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	WATER	2027-12-20
Eli Lilly and Company	RETEVMO	selpercatinib	0002-3977	WATER	2038-04-10
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	WATER	2031-09-28
Eli Lilly and Company	BAQSIMI	glucagon	0002-6145	WATER

Generic drugs containing WATER excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	dulaglutide	0002-1433	WATER
Eli Lilly and Company	galcanezumab-gnlm	0002-1436	WATER
Eli Lilly and Company	ixekizumab	0002-1445	WATER
Eli Lilly and Company	tirzepatide	0002-1506	WATER
Eli Lilly and Company	tirzepatide	0002-2506	WATER

Pharmaceutical Excipient Water Market Dynamics and Financial Trajectory

Last updated: November 3, 2026

Pharmaceutical-grade water is a high-volume, low-margin but strategically critical excipient. Its market value is concentrated in purified water, water for injection, sterile water for injection, and specialty sterile-water presentations. Demand tracks injectable-drug manufacturing, biologics, vaccines, contract development and manufacturing organizations, and expansion of regulated production capacity.

The excipient has limited direct pricing power. Financial performance is determined by system ownership, energy consumption, validation, microbiological control, distribution, container systems, and the cost of production failures. Water itself has no meaningful standalone patent estate, Orange Book listing, or generic-entry barrier. The commercial moat sits in qualified water systems, manufacturing compliance, packaging, and quality-control infrastructure.

What types of pharmaceutical water are used as excipients?

Pharmaceutical water is classified by quality grade, intended use, and manufacturing controls.

Water type	Primary use	Typical quality controls	Commercial form
Purified Water	Oral liquids, nonsterile products, cleaning and processing	Chemical purity, conductivity, total organic carbon, microbial control	Bulk utility or packaged product
Water for Injection	Parenteral manufacturing and formulation	Chemical purity, endotoxin control, microbial control	Bulk utility or packaged product
Sterile Water for Injection	Sterile diluent and injectable products	Sterility, endotoxins, container integrity, particulate control	Single-dose or multidose vials, ampoules, bags
Sterile Water for Irrigation	Surgical and irrigation applications	Sterility, endotoxins, particulate control	Large-volume sterile containers
Bacteriostatic Water for Injection	Diluent containing a preservative, generally benzyl alcohol	Sterility, endotoxins, preservative concentration	Multidose vials

The United States Pharmacopeia defines relevant standards in USP-NF monographs and general chapters, including water quality, conductivity, total organic carbon, microbial enumeration, and bacterial endotoxins [1]. The European Pharmacopoeia and other regional pharmacopoeias impose comparable but not always identical requirements.

Water used in manufacturing is often not sold as a conventional excipient. A drug manufacturer generally generates and distributes water through an internal validated system. Packaged sterile water is a finished pharmaceutical product rather than merely a bulk excipient.

How large is the pharmaceutical water market?

There is no universally reported global market category for "water as a pharmaceutical excipient." Public market reports usually combine pharmaceutical water with water-treatment equipment, purified-water systems, laboratory water, process utilities, or sterile liquid products. Those categories are not interchangeable.

The market therefore has three economic layers:

1. Water-generation and distribution systems. These include pretreatment, reverse osmosis, electrodeionization, ultrafiltration, distillation, storage tanks, distribution loops, sanitization systems, and monitoring equipment.
2. Testing, validation, and maintenance. This includes microbial testing, endotoxin testing, conductivity, total organic carbon, calibration, qualification, preventive maintenance, and system revalidation.
3. Packaged sterile water products. These include sterile water for injection, bacteriostatic water, irrigation water, and specialty diluent presentations.

The first two layers account for much of the industrial expenditure. The water molecule has low unit value, but a compliant pharmaceutical water system can require substantial capital expenditure and recurring quality costs.

What determines pharmaceutical water pricing?

Pricing depends on whether the product is bulk water, packaged sterile water, or a complete water-system service.

Cost driver	Effect on economics
Facility scale	Larger facilities lower unit cost but require greater capital investment
Water grade	WFI and sterile presentations cost more than purified water
Energy	Distillation and thermal sanitization can materially increase operating costs
Packaging	Vials, ampoules, bags, closures, and sterilization add cost
Testing	Endotoxin, microbial, chemical, and particulate testing add recurring expense
Regulatory status	GMP-qualified production commands a premium over technical-grade supply
Supply model	Internal generation reduces transport dependence but raises fixed costs
Water scarcity and utilities	Local water quality and energy prices affect system design
Failure risk	Contamination can cause batch rejection, shutdowns, recalls, and remediation

Bulk pharmaceutical water is often a cost center rather than a high-margin product line. Packaged sterile water has a higher selling price because the price includes container closure systems, sterilization, labeling, batch release, distribution, and regulatory compliance.

What is driving demand for pharmaceutical-grade water?

Demand is linked to pharmaceutical production volume rather than consumer water consumption.

Injectable and biologic manufacturing

Parenteral drugs require stringent water controls. Growth in biologics, vaccines, peptides, cell therapies, and sterile injectables expands demand for WFI systems, sterile diluents, clean utilities, and validated distribution loops.

Biologics manufacturing increases the economic importance of water even when water is not present in the final drug product. Water is used in formulation, equipment cleaning, buffer preparation, chromatography, media preparation, sterilization support, and facility sanitation.

Contract manufacturing

Contract development and manufacturing organizations continue to invest in modular and multi-product facilities. These sites require flexible water systems that can support changing batch sizes and product portfolios. The result is demand for skid-mounted generation units, single-use systems, point-of-use monitoring, and outsourced validation services.

Facility expansion and remediation

Aging water systems require replacement of tanks, loops, heat exchangers, sensors, pumps, and control systems. Regulatory observations involving microbial contamination, inadequate sampling, poor trending, and insufficient sanitization can trigger expensive remediation.

Sterile-water presentations

Packaged sterile water demand follows the volume of injectable drugs, hospital use, reconstitution requirements, irrigation procedures, and pharmacy compounding. Supply interruptions can create shortages even when underlying water-production capacity is adequate because the constraint may sit in vials, closures, sterilization capacity, or finished-product release.

How does the regulatory status of pharmaceutical water affect the market?

Regulation creates recurring demand for qualified systems and testing services.

In the United States, manufacturers must establish written procedures to prevent objectionable microorganisms in drug products and must control facilities, equipment, components, and production processes under current good manufacturing practice requirements [2]. Water systems are subject to qualification, monitoring, sanitation, maintenance, deviation management, and change control.

FDA expectations generally focus on:

• Defined water specifications and intended uses.
• Qualification of generation, storage, and distribution systems.
• Routine chemical and microbiological monitoring.
• Control of biofilm and microbial proliferation.
• Validated sanitization procedures.
• Scientifically justified sampling plans.
• Investigation of adverse trends and excursions.
• Documentation supporting continued state of control.

USP chapters <643>, <645>, <85>, and <1231> are central technical references for total organic carbon, conductivity, bacterial endotoxins, and pharmaceutical water systems [1]. FDA’s current good manufacturing practice regulations provide the enforceable framework [2].

What FDA regulatory status applies to sterile water products?

Sterile Water for Injection, Bacteriostatic Water for Injection, and Sterile Water for Irrigation are drug products regulated under FDA requirements. They are not treated as unregulated commodity excipients when sold in finished sterile containers.

The regulatory burden includes:

• Drug listing and establishment registration.
• Approved labeling.
• Sterility and endotoxin controls.
• Container-closure integrity.
• Stability data.
• Manufacturing-process validation.
• Environmental and aseptic controls.
• Finished-product testing and release.

What is the Orange Book status of pharmaceutical water?

Pharmaceutical water as a bulk excipient has no Orange Book listing. Water is not an active pharmaceutical ingredient with a branded-drug patent profile.

Packaged sterile-water products may be approved drug products, but their regulatory status does not create a conventional patent-centered market structure. Competition is generally based on manufacturing approval, supply reliability, packaging, hospital contracting, and price.

The Orange Book does not operate as a central market database for bulk Purified Water or bulk WFI. There is no standard Paragraph IV pathway directed at water as an excipient.

What patents protect pharmaceutical water systems and formulations?

Water itself is not a practical composition-of-matter patent asset. Patent protection can apply to equipment, purification processes, control systems, container technologies, sterilization methods, or drug formulations that contain water.

Potentially relevant patent categories include:

Patent category	Examples of protected subject matter
Generation systems	Reverse osmosis, electrodeionization, distillation, membrane and hybrid systems
Microbial control	Ozone treatment, ultraviolet treatment, thermal sanitization, chemical sanitization
Monitoring	Inline conductivity, TOC, endotoxin, microbial or process-control systems
Distribution	Loop design, dead-leg reduction, recirculation, heat management
Packaging	Sterile bags, vial systems, ampoules, closures, container coatings
Formulations	Aqueous drug compositions, reconstitution systems, preservative-containing diluents
Manufacturing methods	Water-based purification, formulation, cleaning, or aseptic-processing methods

A formulation patent that claims an aqueous injectable composition may limit a particular drug product. It does not generally provide control over pharmaceutical water as a commodity input. Method-of-use patents may cover the drug administration or therapeutic indication, not the water excipient.

Patent expiration dates therefore vary by equipment supplier, drug sponsor, and packaging technology. No single pharmaceutical-water patent expiration date determines market entry.

Which companies compete in pharmaceutical water systems?

Competition is fragmented across equipment, engineering, testing, and packaged products.

Relevant supplier groups include:

• Water-system engineering companies.
• Pharmaceutical utility integrators.
• Membrane and filtration manufacturers.
• Distillation and heat-sanitization equipment suppliers.
• Monitoring and laboratory-testing providers.
• Contract manufacturers of sterile diluents.
• Large pharmaceutical manufacturers with internal water-generation capabilities.

Major industrial water and life-science equipment companies have participated in pharmaceutical water infrastructure, including Veolia, Merck Millipore, Thermo Fisher Scientific, Sartorius, Pall, Evoqua, and Aquafine-related businesses. Participation differs by geography, product line, and acquisition history. Packaged sterile-water competition includes branded and generic injectable manufacturers, hospital suppliers, and contract manufacturers.

The competitive landscape is less concentrated than the market for many active pharmaceutical ingredients. Qualification history, service coverage, validation support, and response time often matter more than nominal water price.

How strong is the patent estate for pharmaceutical water?

The direct patent estate is weak. The operational barriers are strong.

Direct patent strength

• Water has no meaningful composition-of-matter exclusivity.
• Bulk purified water and WFI are defined by public compendial standards.
• Competing manufacturers can use different validated technologies.
• Patent claims on specific equipment may be designed around or licensed.

Regulatory and operational strength

• Qualification can take months.
• Changing a water source or system can trigger extensive validation.
• Microbial-control failures can halt production.
• Pharmaceutical companies are reluctant to switch systems without documented equivalence.
• Site-specific engineering and historical data create switching costs.

This makes pharmaceutical water a compliance-driven market rather than a patent-driven market. The strongest economic moat is a validated, reliable supply system embedded in a regulated facility.

What manufacturing and intellectual-property barriers affect market entry?

The principal barriers are manufacturing and quality barriers.

A new supplier must demonstrate control over source water, pretreatment, purification, storage, distribution, sanitation, testing, and records. For sterile packaged products, the supplier must also qualify filling, sterilization, container closure, labeling, release, and distribution.

Manufacturing risks include:

• Biofilm formation.
• Endotoxin excursions.
• Inadequate system sanitization.
• Stagnation and dead legs.
• Sensor drift.
• Incomplete sampling.
• Container-closure failures.
• Sterility failures.
• Inconsistent source-water quality.
• Supply-chain interruptions for containers and closures.

Intellectual-property barriers are usually secondary. Freedom-to-operate analysis is more important for advanced purification, monitoring, sterilization, and packaging equipment than for the water itself.

What litigation and settlement risks affect pharmaceutical water?

There is no standard class of Paragraph IV litigation focused on bulk pharmaceutical water. Litigation risk generally arises from:

• Contamination-related product liability.
• Contract disputes over water-system performance.
• Patent disputes involving purification equipment.
• Trade-secret disputes involving system design or control software.
• Regulatory enforcement after failed inspections.
• Product recalls involving sterile-water presentations.
• Supply agreements and manufacturing deviations.

Settlement agreements are more likely to concern equipment licensing, contract manufacturing, or drug-product patents than water as an excipient. A drug sponsor’s settlement over an aqueous formulation does not necessarily restrict competing access to pharmaceutical-grade water.

When does pharmaceutical water lose exclusivity?

Bulk pharmaceutical water has no conventional exclusivity period. Once a manufacturer can meet applicable pharmacopoeial and GMP requirements, it can compete.

Exclusivity may apply indirectly to:

• A patented water-generation technology.
• A proprietary monitoring platform.
• A sterile-water drug product with approved labeling.
• A drug formulation containing water.
• A contract manufacturing arrangement.
• A facility-specific regulatory approval.

Those rights expire or change independently. There is no universal loss-of-exclusivity date for purified water or WFI.

What is the financial trajectory for pharmaceutical water?

The medium-term trajectory is structurally positive in volume and infrastructure spending, but margin growth is likely to remain uneven.

Period	Financial direction	Primary drivers
Near term	Stable to moderate growth	Injectable production, biologics, maintenance, remediation
Medium term	Higher capital expenditure	New sterile facilities, CDMO expansion, WFI capacity
Longer term	More automation and outsourcing	Remote monitoring, modular systems, single-use technologies

Revenue growth is likely to come from system installation, upgrades, validation, monitoring, and service contracts rather than from the raw cost of water. Energy-efficient membrane systems may reduce operating costs, while stricter monitoring and microbial-control expectations increase compliance spending.

The main downside risks are:

• Delayed pharmaceutical construction projects.
• Reduced biologics capital expenditure.
• Energy-price volatility.
• Water scarcity and utility restrictions.
• Consolidation among pharmaceutical manufacturers.
• In-house engineering by large drug companies.
• Failure of suppliers to maintain service coverage.
• Commodity pressure on packaged sterile-water pricing.

Revenue exposure is greatest for equipment manufacturers, validation contractors, sterile-product manufacturers, and suppliers serving injectable and biologic facilities. It is lower for companies exposed only to bulk water volume.

How does pharmaceutical water compare with other excipients?

Water differs from conventional pharmaceutical excipients because it is both an ingredient and a manufacturing utility.

Attribute	Pharmaceutical water	Conventional excipient
Composition-of-matter patents	Minimal	Possible for specialty materials
Regulatory standardization	High	Varies by excipient
Internal production	Common	Less common
Transport economics	Poor for bulk water	Usually favorable
Contamination risk	High and continuous	Usually batch-specific
Pricing power	Low for bulk supply	Higher for differentiated excipients
Switching cost	High after system qualification	Moderate to high depending on formulation
Market moat	Compliance and infrastructure	Quality, formulation performance, and IP

Water has lower direct gross-margin potential than specialty excipients but greater facility-wide importance. A water-system failure can affect many products simultaneously.

Key Takeaways

• Pharmaceutical water is a critical excipient and manufacturing utility, not a conventional high-margin API-like market.
• Purified Water, WFI, and sterile water have distinct quality, regulatory, and commercial profiles.
• The market is not reported consistently as a standalone category.
• Financial growth is concentrated in water systems, validation, monitoring, maintenance, and sterile packaging.
• Water has no meaningful direct patent exclusivity or Orange Book protection.
• The main barriers are GMP qualification, microbial control, endotoxin control, system validation, and reliable supply.
• Injectable drugs, biologics, vaccines, CDMOs, and sterile-facility expansion are the main demand drivers.
• Packaged sterile-water products have greater commercial value than bulk water because they include regulated manufacturing and container systems.
• Litigation risk is concentrated in contamination, contracts, equipment patents, and finished-product liability.
• The strongest investment exposure is in pharmaceutical water infrastructure and services rather than in the commodity water input.

FAQs

Is water considered an active pharmaceutical ingredient?

No. Water is generally an excipient, solvent, diluent, processing aid, or manufacturing utility. Its regulatory classification depends on its grade and use.

Can pharmaceutical companies buy WFI from outside suppliers?

Yes, but many facilities generate WFI internally. External supply must meet applicable specifications and remain under the drug manufacturer’s qualification and change-control program.

Is Water for Injection the same as sterile water for injection?

No. WFI is a bulk pharmaceutical water grade. Sterile Water for Injection is a finished sterile drug product packaged in a container-closure system.

Are pharmaceutical water systems included in FDA drug approvals?

Water systems are generally evaluated as part of facility, equipment, process, and GMP inspections. They are not usually listed as standalone drug substances in an approval pathway.

What is the largest commercial risk in pharmaceutical water production?

Microbial or endotoxin contamination is the largest operational risk because it can cause batch rejection, production interruption, regulatory findings, recall exposure, and costly remediation.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters <85>, <643>, <645>, and <1231>. USP Convention.

2. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Part 211. U.S. Department of Health and Human Services.

3. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Water for pharmaceutical use. Council of Europe.

4. World Health Organization. (2017). WHO good manufacturing practices: Water for pharmaceutical use. World Health Organization.

5. U.S. Food and Drug Administration. (2014). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice. U.S. Department of Health and Human Services.